A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Dezapelisib (Primary) ; Itacitinib (Primary)
- Indications Chronic lymphocytic leukaemia; Hairy cell leukaemia; Hodgkin's disease; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Incyte Corporation
- 18 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
- 18 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Dec 2017.
- 18 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.